<DOC>
	<DOC>NCT01891669</DOC>
	<brief_summary>To assess the safety and tolerability at increasing dose levels of PF-06263507 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.</brief_summary>
	<brief_title>A Study Of PF-06263507 In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for which no standard therapy is available. Performance Status of 0 or 1. Adequate bone marrow, kidney, liver, and heart function. Brain metastases requiring steroids. Major surgery or anticancer therapy within 4 weeks of study treatment start. Active bacterial, fungal or viral infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>ADC 5T4</keyword>
	<keyword>PF-06263507</keyword>
	<keyword>solid tumors</keyword>
	<keyword>lung cancer</keyword>
	<keyword>breast cancer</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>cancer</keyword>
	<keyword>tumors</keyword>
	<keyword>neoplasm metastasis</keyword>
</DOC>